The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biologics and Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Synopsis
The global Biologics and Biosimilars market size was US$ 441320 million in 2024 and is forecast to a readjusted size of US$ 784010 million by 2031 with a CAGR of 8.7% during the forecast period 2025-2031.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product"s patent expires. Reference to the innovator product is an integral component of the approval.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
The global Biologics and Biosimilars market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
By Type: (Dominant Segment vs High-Margin Innovation)
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Hospital
Retail Pharmacy
Other
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Roche in Europe)
- Emerging Product Trends: Monoclonal Antibodies adoption vs. Interferon premiumization
- Demand-Side Dynamics: Hospital growth in China vs. Retail Pharmacy potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Middle East & Africa
Southeast Asia
South America
Japan
China
South Korea
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Biologics and Biosimilars market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Interferon in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Retail Pharmacy in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Biologics and Biosimilars value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
The global Biologics and Biosimilars market size was US$ 441320 million in 2024 and is forecast to a readjusted size of US$ 784010 million by 2031 with a CAGR of 8.7% during the forecast period 2025-2031.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product"s patent expires. Reference to the innovator product is an integral component of the approval.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
The global Biologics and Biosimilars market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
By Type: (Dominant Segment vs High-Margin Innovation)
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Hospital
Retail Pharmacy
Other
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Roche in Europe)
- Emerging Product Trends: Monoclonal Antibodies adoption vs. Interferon premiumization
- Demand-Side Dynamics: Hospital growth in China vs. Retail Pharmacy potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Middle East & Africa
Southeast Asia
South America
Japan
China
South Korea
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Biologics and Biosimilars market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Interferon in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Retail Pharmacy in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Biologics and Biosimilars value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Index1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biologics and Biosimilars Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Biologics and Biosimilars Revenue Market Share by Region (2020-2025)
2.4 Global Biologics and Biosimilars Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Biologics and Biosimilars Market Size and Prospective (2020-2031)
2.5.2 Europe Biologics and Biosimilars Market Size and Prospective (2020-2031)
2.5.3 Middle East & Africa Biologics and Biosimilars Market Size and Prospective (2020-2031)
2.5.4 Southeast Asia Biologics and Biosimilars Market Size and Prospective (2020-2031)
2.5.5 South America Biologics and Biosimilars Market Size and Prospective (2020-2031)
2.5.6 Japan Biologics and Biosimilars Market Size and Prospective (2020-2031)
2.5.7 China Biologics and Biosimilars Market Size and Prospective (2020-2031)
2.5.8 South Korea Biologics and Biosimilars Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Biologics and Biosimilars Historic Market Size by Type (2020-2025)
3.2 Global Biologics and Biosimilars Forecasted Market Size by Type (2026-2031)
3.3 Different Types Biologics and Biosimilars Representative Players
4 Breakdown Data by Application
4.1 Global Biologics and Biosimilars Historic Market Size by Application (2020-2025)
4.2 Global Biologics and Biosimilars Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Biologics and Biosimilars Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Biologics and Biosimilars Players by Revenue (2020-2025)
5.1.2 Global Biologics and Biosimilars Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Biologics and Biosimilars Revenue
5.4 Global Biologics and Biosimilars Market Concentration Analysis
5.4.1 Global Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Biologics and Biosimilars Revenue in 2024
5.5 Global Key Players of Biologics and Biosimilars Head office and Area Served
5.6 Global Key Players of Biologics and Biosimilars, Product and Application
5.7 Global Key Players of Biologics and Biosimilars, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Biologics and Biosimilars Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Biologics and Biosimilars Market Size by Type (2020-2025)
6.1.2.2 North America Biologics and Biosimilars Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Biologics and Biosimilars Market Size by Application (2020-2025)
6.1.3.2 North America Biologics and Biosimilars Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Biologics and Biosimilars Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Biologics and Biosimilars Market Size by Type (2020-2025)
6.2.2.2 Europe Biologics and Biosimilars Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Biologics and Biosimilars Market Size by Application (2020-2025)
6.2.3.2 Europe Biologics and Biosimilars Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 Middle East & Africa Market: Players, Segments and Downstream
6.3.1 Middle East & Africa Biologics and Biosimilars Revenue by Company (2020-2025)
6.3.2 Middle East & Africa Market Size by Type
6.3.2.1 Middle East & Africa Biologics and Biosimilars Market Size by Type (2020-2025)
6.3.2.2 Middle East & Africa Biologics and Biosimilars Market Share by Type (2020-2025)
6.3.3 Middle East & Africa Market Size by Application
6.3.3.1 Middle East & Africa Biologics and Biosimilars Market Size by Application (2020-2025)
6.3.3.2 Middle East & Africa Biologics and Biosimilars Market Share by Application (2020-2025)
6.3.4 Middle East & Africa Market Trend and Opportunities
6.4 Southeast Asia Market: Players, Segments and Downstream
6.4.1 Southeast Asia Biologics and Biosimilars Revenue by Company (2020-2025)
6.4.2 Southeast Asia Market Size by Type
6.4.2.1 Southeast Asia Biologics and Biosimilars Market Size by Type (2020-2025)
6.4.2.2 Southeast Asia Biologics and Biosimilars Market Share by Type (2020-2025)
6.4.3 Southeast Asia Market Size by Application
6.4.3.1 Southeast Asia Biologics and Biosimilars Market Size by Application (2020-2025)
6.4.3.2 Southeast Asia Biologics and Biosimilars Market Share by Application (2020-2025)
6.4.4 Southeast Asia Market Trend and Opportunities
6.5 South America Market: Players, Segments and Downstream
6.5.1 South America Biologics and Biosimilars Revenue by Company (2020-2025)
6.5.2 South America Market Size by Type
6.5.2.1 South America Biologics and Biosimilars Market Size by Type (2020-2025)
6.5.2.2 South America Biologics and Biosimilars Market Share by Type (2020-2025)
6.5.3 South America Market Size by Application
6.5.3.1 South America Biologics and Biosimilars Market Size by Application (2020-2025)
6.5.3.2 South America Biologics and Biosimilars Market Share by Application (2020-2025)
6.5.4 South America Market Trend and Opportunities
6.6 Japan Market: Players, Segments and Downstream
6.6.1 Japan Biologics and Biosimilars Revenue by Company (2020-2025)
6.6.2 Japan Market Size by Type
6.6.2.1 Japan Biologics and Biosimilars Market Size by Type (2020-2025)
6.6.2.2 Japan Biologics and Biosimilars Market Share by Type (2020-2025)
6.6.3 Japan Market Size by Application
6.6.3.1 Japan Biologics and Biosimilars Market Size by Application (2020-2025)
6.6.3.2 Japan Biologics and Biosimilars Market Share by Application (2020-2025)
6.6.4 Japan Market Trend and Opportunities
7 Key Players Profiles
7.1 Roche
7.1.1 Roche Company Details
7.1.2 Roche Business Overview
7.1.3 Roche Biologics and Biosimilars Introduction
7.1.4 Roche Revenue in Biologics and Biosimilars Business (2020-2025)
7.1.5 Roche Recent Development
7.2 Amgen
7.2.1 Amgen Company Details
7.2.2 Amgen Business Overview
7.2.3 Amgen Biologics and Biosimilars Introduction
7.2.4 Amgen Revenue in Biologics and Biosimilars Business (2020-2025)
7.2.5 Amgen Recent Development
7.3 AbbVie
7.3.1 AbbVie Company Details
7.3.2 AbbVie Business Overview
7.3.3 AbbVie Biologics and Biosimilars Introduction
7.3.4 AbbVie Revenue in Biologics and Biosimilars Business (2020-2025)
7.3.5 AbbVie Recent Development
7.4 Sanofi
7.4.1 Sanofi Company Details
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Biologics and Biosimilars Introduction
7.4.4 Sanofi Revenue in Biologics and Biosimilars Business (2020-2025)
7.4.5 Sanofi Recent Development
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Company Details
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Biologics and Biosimilars Introduction
7.5.4 Johnson & Johnson Revenue in Biologics and Biosimilars Business (2020-2025)
7.5.5 Johnson & Johnson Recent Development
7.6 Pfizer
7.6.1 Pfizer Company Details
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Biologics and Biosimilars Introduction
7.6.4 Pfizer Revenue in Biologics and Biosimilars Business (2020-2025)
7.6.5 Pfizer Recent Development
7.7 Novo Nordisk
7.7.1 Novo Nordisk Company Details
7.7.2 Novo Nordisk Business Overview
7.7.3 Novo Nordisk Biologics and Biosimilars Introduction
7.7.4 Novo Nordisk Revenue in Biologics and Biosimilars Business (2020-2025)
7.7.5 Novo Nordisk Recent Development
7.8 Eli Lilly
7.8.1 Eli Lilly Company Details
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Biologics and Biosimilars Introduction
7.8.4 Eli Lilly Revenue in Biologics and Biosimilars Business (2020-2025)
7.8.5 Eli Lilly Recent Development
7.9 Novartis
7.9.1 Novartis Company Details
7.9.2 Novartis Business Overview
7.9.3 Novartis Biologics and Biosimilars Introduction
7.9.4 Novartis Revenue in Biologics and Biosimilars Business (2020-2025)
7.9.5 Novartis Recent Development
7.10 Merck
7.10.1 Merck Company Details
7.10.2 Merck Business Overview
7.10.3 Merck Biologics and Biosimilars Introduction
7.10.4 Merck Revenue in Biologics and Biosimilars Business (2020-2025)
7.10.5 Merck Recent Development
7.11 Biogen
7.11.1 Biogen Company Details
7.11.2 Biogen Business Overview
7.11.3 Biogen Biologics and Biosimilars Introduction
7.11.4 Biogen Revenue in Biologics and Biosimilars Business (2020-2025)
7.11.5 Biogen Recent Development
7.12 Celltrion
7.12.1 Celltrion Company Details
7.12.2 Celltrion Business Overview
7.12.3 Celltrion Biologics and Biosimilars Introduction
7.12.4 Celltrion Revenue in Biologics and Biosimilars Business (2020-2025)
7.12.5 Celltrion Recent Development
7.13 Sobi
7.13.1 Sobi Company Details
7.13.2 Sobi Business Overview
7.13.3 Sobi Biologics and Biosimilars Introduction
7.13.4 Sobi Revenue in Biologics and Biosimilars Business (2020-2025)
7.13.5 Sobi Recent Development
7.14 3SBIO
7.14.1 3SBIO Company Details
7.14.2 3SBIO Business Overview
7.14.3 3SBIO Biologics and Biosimilars Introduction
7.14.4 3SBIO Revenue in Biologics and Biosimilars Business (2020-2025)
7.14.5 3SBIO Recent Development
7.15 Changchun High Tech
7.15.1 Changchun High Tech Company Details
7.15.2 Changchun High Tech Business Overview
7.15.3 Changchun High Tech Biologics and Biosimilars Introduction
7.15.4 Changchun High Tech Revenue in Biologics and Biosimilars Business (2020-2025)
7.15.5 Changchun High Tech Recent Development
7.16 Kanghong Pharma
7.16.1 Kanghong Pharma Company Details
7.16.2 Kanghong Pharma Business Overview
7.16.3 Kanghong Pharma Biologics and Biosimilars Introduction
7.16.4 Kanghong Pharma Revenue in Biologics and Biosimilars Business (2020-2025)
7.16.5 Kanghong Pharma Recent Development
7.17 Innovent Biologics
7.17.1 Innovent Biologics Company Details
7.17.2 Innovent Biologics Business Overview
7.17.3 Innovent Biologics Biologics and Biosimilars Introduction
7.17.4 Innovent Biologics Revenue in Biologics and Biosimilars Business (2020-2025)
7.17.5 Innovent Biologics Recent Development
7.18 Gan&Lee
7.18.1 Gan&Lee Company Details
7.18.2 Gan&Lee Business Overview
7.18.3 Gan&Lee Biologics and Biosimilars Introduction
7.18.4 Gan&Lee Revenue in Biologics and Biosimilars Business (2020-2025)
7.18.5 Gan&Lee Recent Development
7.19 Tonghua Dongbao
7.19.1 Tonghua Dongbao Company Details
7.19.2 Tonghua Dongbao Business Overview
7.19.3 Tonghua Dongbao Biologics and Biosimilars Introduction
7.19.4 Tonghua Dongbao Revenue in Biologics and Biosimilars Business (2020-2025)
7.19.5 Tonghua Dongbao Recent Development
7.20 United Laboratory
7.20.1 United Laboratory Company Details
7.20.2 United Laboratory Business Overview
7.20.3 United Laboratory Biologics and Biosimilars Introduction
7.20.4 United Laboratory Revenue in Biologics and Biosimilars Business (2020-2025)
7.20.5 United Laboratory Recent Development
8 Biologics and Biosimilars Market Dynamics
8.1 Biologics and Biosimilars Industry Trends
8.2 Biologics and Biosimilars Market Drivers
8.3 Biologics and Biosimilars Market Challenges
8.4 Biologics and Biosimilars Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of TablesList of Tables
Table 1. Global Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Biologics and Biosimilars Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Biologics and Biosimilars Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Biologics and Biosimilars Revenue Share by Region (2020-2025)
Table 6. Global Biologics and Biosimilars Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Biologics and Biosimilars Revenue Share Forecast by Region (2026-2031)
Table 8. Global Biologics and Biosimilars Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Biologics and Biosimilars Revenue Market Share by Type (2020-2025)
Table 10. Global Biologics and Biosimilars Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Biologics and Biosimilars Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Biologics and Biosimilars Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Biologics and Biosimilars Revenue Market Share by Application (2020-2025)
Table 15. Global Biologics and Biosimilars Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Biologics and Biosimilars Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Biologics and Biosimilars Application
Table 18. Global Biologics and Biosimilars Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Biologics and Biosimilars Market Share by Players (2020-2025)
Table 20. Global Top Biologics and Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics and Biosimilars as of 2024)
Table 21. Ranking of Global Top Biologics and Biosimilars Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Biologics and Biosimilars Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Biologics and Biosimilars, Headquarters and Area Served
Table 24. Global Key Players of Biologics and Biosimilars, Product and Application
Table 25. Global Key Players of Biologics and Biosimilars, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Biologics and Biosimilars Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Biologics and Biosimilars Revenue Market Share by Company (2020-2025)
Table 29. North America Biologics and Biosimilars Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Biologics and Biosimilars Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Biologics and Biosimilars Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Biologics and Biosimilars Revenue Market Share by Company (2020-2025)
Table 33. Europe Biologics and Biosimilars Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Biologics and Biosimilars Market Size by Application (2020-2025) & (US$ Million)
Table 35. Middle East & Africa Biologics and Biosimilars Revenue by Company (2020-2025) & (US$ Million)
Table 36. Middle East & Africa Biologics and Biosimilars Revenue Market Share by Company (2020-2025)
Table 37. Middle East & Africa Biologics and Biosimilars Market Size by Type (2020-2025) & (US$ Million)
Table 38. Middle East & Africa Biologics and Biosimilars Market Size by Application (2020-2025) & (US$ Million)
Table 39. Southeast Asia Biologics and Biosimilars Revenue by Company (2020-2025) & (US$ Million)
Table 40. Southeast Asia Biologics and Biosimilars Revenue Market Share by Company (2020-2025)
Table 41. Southeast Asia Biologics and Biosimilars Market Size by Type (2020-2025) & (US$ Million)
Table 42. Southeast Asia Biologics and Biosimilars Market Size by Application (2020-2025) & (US$ Million)
Table 43. South America Biologics and Biosimilars Revenue by Company (2020-2025) & (US$ Million)
Table 44. South America Biologics and Biosimilars Revenue Market Share by Company (2020-2025)
Table 45. South America Biologics and Biosimilars Market Size by Type (2020-2025) & (US$ Million)
Table 46. South America Biologics and Biosimilars Market Size by Application (2020-2025) & (US$ Million)
Table 47. Japan Biologics and Biosimilars Revenue by Company (2020-2025) & (US$ Million)
Table 48. Japan Biologics and Biosimilars Revenue Market Share by Company (2020-2025)
Table 49. Japan Biologics and Biosimilars Market Size by Type (2020-2025) & (US$ Million)
Table 50. Japan Biologics and Biosimilars Market Size by Application (2020-2025) & (US$ Million)
Table 51. Roche Company Details
Table 52. Roche Business Overview
Table 53. Roche Biologics and Biosimilars Product
Table 54. Roche Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 55. Roche Recent Development
Table 56. Amgen Company Details
Table 57. Amgen Business Overview
Table 58. Amgen Biologics and Biosimilars Product
Table 59. Amgen Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 60. Amgen Recent Development
Table 61. AbbVie Company Details
Table 62. AbbVie Business Overview
Table 63. AbbVie Biologics and Biosimilars Product
Table 64. AbbVie Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 65. AbbVie Recent Development
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Biologics and Biosimilars Product
Table 69. Sanofi Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. Johnson & Johnson Company Details
Table 72. Johnson & Johnson Business Overview
Table 73. Johnson & Johnson Biologics and Biosimilars Product
Table 74. Johnson & Johnson Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 75. Johnson & Johnson Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Biologics and Biosimilars Product
Table 79. Pfizer Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Novo Nordisk Company Details
Table 82. Novo Nordisk Business Overview
Table 83. Novo Nordisk Biologics and Biosimilars Product
Table 84. Novo Nordisk Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 85. Novo Nordisk Recent Development
Table 86. Eli Lilly Company Details
Table 87. Eli Lilly Business Overview
Table 88. Eli Lilly Biologics and Biosimilars Product
Table 89. Eli Lilly Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 90. Eli Lilly Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Biologics and Biosimilars Product
Table 94. Novartis Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. Merck Company Details
Table 97. Merck Business Overview
Table 98. Merck Biologics and Biosimilars Product
Table 99. Merck Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 100. Merck Recent Development
Table 101. Biogen Company Details
Table 102. Biogen Business Overview
Table 103. Biogen Biologics and Biosimilars Product
Table 104. Biogen Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 105. Biogen Recent Development
Table 106. Celltrion Company Details
Table 107. Celltrion Business Overview
Table 108. Celltrion Biologics and Biosimilars Product
Table 109. Celltrion Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 110. Celltrion Recent Development
Table 111. Sobi Company Details
Table 112. Sobi Business Overview
Table 113. Sobi Biologics and Biosimilars Product
Table 114. Sobi Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 115. Sobi Recent Development
Table 116. 3SBIO Company Details
Table 117. 3SBIO Business Overview
Table 118. 3SBIO Biologics and Biosimilars Product
Table 119. 3SBIO Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 120. 3SBIO Recent Development
Table 121. Changchun High Tech Company Details
Table 122. Changchun High Tech Business Overview
Table 123. Changchun High Tech Biologics and Biosimilars Product
Table 124. Changchun High Tech Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 125. Changchun High Tech Recent Development
Table 126. Kanghong Pharma Company Details
Table 127. Kanghong Pharma Business Overview
Table 128. Kanghong Pharma Biologics and Biosimilars Product
Table 129. Kanghong Pharma Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 130. Kanghong Pharma Recent Development
Table 131. Innovent Biologics Company Details
Table 132. Innovent Biologics Business Overview
Table 133. Innovent Biologics Biologics and Biosimilars Product
Table 134. Innovent Biologics Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 135. Innovent Biologics Recent Development
Table 136. Gan&Lee Company Details
Table 137. Gan&Lee Business Overview
Table 138. Gan&Lee Biologics and Biosimilars Product
Table 139. Gan&Lee Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 140. Gan&Lee Recent Development
Table 141. Tonghua Dongbao Company Details
Table 142. Tonghua Dongbao Business Overview
Table 143. Tonghua Dongbao Biologics and Biosimilars Product
Table 144. Tonghua Dongbao Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 145. Tonghua Dongbao Recent Development
Table 146. United Laboratory Company Details
Table 147. United Laboratory Business Overview
Table 148. United Laboratory Biologics and Biosimilars Product
Table 149. United Laboratory Revenue in Biologics and Biosimilars Business (2020-2025) & (US$ Million)
Table 150. United Laboratory Recent Development
Table 151. Biologics and Biosimilars Market Trends
Table 152. Biologics and Biosimilars Market Drivers
Table 153. Biologics and Biosimilars Market Challenges
Table 154. Biologics and Biosimilars Market Restraints
Table 155. Research Programs/Design for This Report
Table 156. Key Data Information from Secondary Sources
Table 157. Key Data Information from Primary Sources
List of Figures
Figure 1. Biologics and Biosimilars Product Picture
Figure 2. Global Biologics and Biosimilars Market Share by Type: 2024 VS 2031
Figure 3. Monoclonal Antibodies Features
Figure 4. Interferon Features
Figure 5. Insulin Features
Figure 6. Vaccines Features
Figure 7. Others Features
Figure 8. Global Biologics and Biosimilars Market Share by Application: 2024 VS 2031
Figure 9. Hospital
Figure 10. Retail Pharmacy
Figure 11. Other
Figure 12. Biologics and Biosimilars Report Years Considered
Figure 13. Global Biologics and Biosimilars Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Biologics and Biosimilars Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Biologics and Biosimilars Revenue Market Share by Region: 2020 VS 2024
Figure 16. North America Biologics and Biosimilars Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Europe Biologics and Biosimilars Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Middle East & Africa Biologics and Biosimilars Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. Southeast Asia Biologics and Biosimilars Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. South America Biologics and Biosimilars Revenue (US$ Million) Growth Rate (2020-2031)
Figure 21. Japan Biologics and Biosimilars Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. China Biologics and Biosimilars Revenue (US$ Million) Growth Rate (2020-2031)
Figure 23. South Korea Biologics and Biosimilars Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. Global Biologics and Biosimilars Market Share by Players in 2024
Figure 25. Global Top Biologics and Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics and Biosimilars as of 2024)
Figure 26. The Top 10 and 5 Players Market Share by Biologics and Biosimilars Revenue in 2024
Figure 27. North America Biologics and Biosimilars Market Share by Type (2020-2025)
Figure 28. North America Biologics and Biosimilars Market Share by Application (2020-2025)
Figure 29. Europe Biologics and Biosimilars Market Share by Type (2020-2025)
Figure 30. Europe Biologics and Biosimilars Market Share by Application (2020-2025)
Figure 31. Middle East & Africa Biologics and Biosimilars Market Share by Type (2020-2025)
Figure 32. Middle East & Africa Biologics and Biosimilars Market Share by Application (2020-2025)
Figure 33. Southeast Asia Biologics and Biosimilars Market Share by Type (2020-2025)
Figure 34. Southeast Asia Biologics and Biosimilars Market Share by Application (2020-2025)
Figure 35. South America Biologics and Biosimilars Market Share by Type (2020-2025)
Figure 36. South America Biologics and Biosimilars Market Share by Application (2020-2025)
Figure 37. Japan Biologics and Biosimilars Market Share by Type (2020-2025)
Figure 38. Japan Biologics and Biosimilars Market Share by Application (2020-2025)
Figure 39. Roche Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 40. Amgen Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 41. AbbVie Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 42. Sanofi Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 43. Johnson & Johnson Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 44. Pfizer Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 45. Novo Nordisk Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 46. Eli Lilly Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 47. Novartis Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 48. Merck Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 49. Biogen Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 50. Celltrion Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 51. Sobi Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 52. 3SBIO Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 53. Changchun High Tech Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 54. Kanghong Pharma Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 55. Innovent Biologics Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 56. Gan&Lee Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 57. Tonghua Dongbao Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 58. United Laboratory Revenue Growth Rate in Biologics and Biosimilars Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
